Precision measurement company Mettler-Toledo (NYSE: MTD) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.6% year on year to $883.7 million. Its non-GAAP profit of $8.19 per share was 3.9% above analysts’ consensus estimates.
Is now the time to buy MTD? Find out in our full research report (it’s free).
Mettler-Toledo (MTD) Q1 CY2025 Highlights:
- Revenue: $883.7 million vs analyst estimates of $875.1 million (4.6% year-on-year decline, 1% beat)
- Adjusted EPS: $8.19 vs analyst estimates of $7.88 (3.9% beat)
- Adjusted EBITDA: $266.4 million vs analyst estimates of $246.3 million (30.1% margin, 8.2% beat)
- Management lowered its full-year Adjusted EPS guidance to $41.63 at the midpoint, a 2.5% decrease
- Operating Margin: 24.8%, down from 26.9% in the same quarter last year
- Free Cash Flow Margin: 20.1%, up from 18.6% in the same quarter last year
- Organic Revenue fell 2.7% year on year (0.1% in the same quarter last year)
- Market Capitalization: $23.76 billion
StockStory’s Take
Mettler-Toledo’s first quarter results were shaped by ongoing global trade disruptions, cautious customer behavior, and a sharp focus on supply chain optimization. CEO Patrick Kaltenbach highlighted underlying growth in laboratory and process analytics, excluding shipping recovery impacts from the prior year, and emphasized the company’s ability to offset volume headwinds with pricing actions and operational improvements. The quarter also saw mixed performance across regions, with China and core industrial markets experiencing particular softness, while process analytics and product inspection segments showed resilience.
Looking ahead, management cited continued uncertainty driven by tariffs, slower macroeconomic trends, and delayed customer investment—especially in China and the industrial segment. CFO Shawn Vadala explained the company’s lowered full-year earnings guidance and outlined ongoing mitigation efforts, including price increases, surcharges, and accelerated supply chain moves to counteract a projected $115 million annual tariff headwind. Kaltenbach stated, "We remain agile to respond to changes in market conditions and convinced of the long-term opportunity in our end markets."
Key Insights from Management’s Remarks
Mettler-Toledo’s leadership underscored the quarter’s operational complexity and the evolving external environment, which shaped both the Q1 results and the company’s outlook for the rest of the year.
-
Tariff Impact and Mitigation: Management estimated $115 million in annual tariff costs, with actions underway to fully offset this by next year. These include supply chain shifts, cost savings, and pricing adjustments, though a near-term margin headwind is expected.
-
Supply Chain Resilience Initiatives: The company accelerated manufacturing expansion in Mexico to reduce exposure to China and diversify sourcing, a move designed to enhance flexibility and buffer against future trade policy changes.
-
Laboratory and Process Analytics Growth: Excluding prior-year shipping recoveries, laboratory and process analytics segments saw growth, benefiting from innovations such as digital sensors for bioprocessing and new titration instruments, particularly in biopharma markets.
-
Core Industrial and Food Retail Weakness: Core industrial sales declined modestly, and food retail contracted as anticipated. Delays in large industrial projects and cautious customer spending—especially in China—contributed to the softness.
-
Service Business Expansion: Service revenues increased 6% in Q1, supported by targeted investments in sales programs and telesales, with management expressing confidence in the sustainability of this growth due to a large installed base and ongoing service initiatives.
Drivers of Future Performance
Management’s outlook for the remainder of the year is shaped by external tariff risks, continued supply chain adaptation, and persistent macroeconomic uncertainty in key markets, particularly China.
-
Tariff Mitigation Execution: The effectiveness and timing of supply chain relocation efforts, price increases, and surcharges will be crucial for offsetting tariff-driven margin pressure. Management expects most mitigation actions to be realized by the end of the year.
-
Customer Investment Timing: Delayed customer investment, especially in China and core industrial, is expected to persist, with volume growth in the second half of the year likely to remain similar to the first half barring a significant shift in macro conditions.
-
Growth in Biopharma and Service: Innovations in process analytics and laboratory automation, primarily serving biopharma, are expected to drive relative strength, while the service business—backed by a growing installed base—is positioned as a stable contributor to revenue and profitability.
Top Analyst Questions
-
Dan Leonard (UBS): Asked about updated China growth forecasts and the impact of onshoring. Management projected slight declines in China, with lab up low single digits and industrial down. They noted onshoring is not yet a major revenue driver.
-
Patrick Donnelly (Citi): Inquired about the breakdown of tariff impacts and pricing offsets. CFO Vadala detailed that supply chain moves, cost savings, and higher pricing should largely offset tariff costs over time, though near-term headwinds remain.
-
Brandon Couillard (Wells Fargo): Sought clarity on whether order delays were concentrated in China or core industrial globally. Management confirmed customer hesitation and project delays are mainly a China issue, with U.S. delays linked to specific large projects.
-
Rachel Vatnsdal (JPMorgan): Asked how customer caution and macro uncertainty affect second quarter versus back half expectations. Management replied that volume growth is expected to remain flat between halves, with pricing providing incremental support later in the year.
-
Catherine Schulte (Baird): Queried about exposure to potential new European tariffs and capital deployment. Management confirmed significant U.S. imports from Switzerland and no change to buyback plans, regardless of share price movements.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will closely monitor (1) the pace and effectiveness of tariff mitigation initiatives, including supply chain relocation and pricing actions, (2) signs of stabilization or renewed investment among industrial and laboratory customers—particularly in China, and (3) sustained growth in process analytics and service revenues. Successful execution in these areas will be key to supporting margins and meeting revised earnings targets.
Mettler-Toledo currently trades at a forward P/E ratio of 26.3×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report.
Our Favorite Stocks Right Now
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
